Roche's Avastin Fails in Early-Stage Colon Cancer Study

Roche's top-selling cancer-fighting drug Avastin has hit another roadblock in testing. In a Phase III study, Avastin failed to improve disease-free survival in early-stage colon cancer patients, the pharmaceutical giant reported.

Setback for Roche and Immunogen Breast Cancer Drug

The FDA denied accelerated approval of Roche's trastuzumab-DM1 (T-DM1) license application. T-DM1 is a potential breast cancer treatment. Roche will continue with its trials and plans a global regulatory submission in mid-2012.

Roche Strikes $1.1 Billion Deal With Aileron

Swiss pharmaceutical giant Roche has struck a deal with Aileron Therapeutics worth up to $1.1 billion to gain access to a new class of drugs called stapled peptide therapeutics. This could yield new ways to attack hard-to-reach disease targets.